Cargando…
Mycophenolate versus Cyclophosphamide for Lupus Nephritis
Systemic lupus erythematosus is common in our country, and renal involvement is an important cause of chronic kidney disease. This study was aimed at comparing the three regimens, i.e., cyclophosphamide-based regimes (low dose and high dose) and mycophenolate mofetil (MMF)-based regime and determini...
Autores principales: | Sahay, M., Saivani, Y., Ismal, K., Vali, P. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830807/ https://www.ncbi.nlm.nih.gov/pubmed/29515299 http://dx.doi.org/10.4103/ijn.IJN_2_16 |
Ejemplares similares
-
Splenorenal graft: A safe and effective treatment for renovascular hypertension
por: Sahay, M., et al.
Publicado: (2015) -
Maternal drugs and neonatal renal failure
por: Sahay, M., et al.
Publicado: (2014) -
Mycophenolate or Cyclophosphamide in Lupus Nephritis: Which One to Use in Indian Patients?
por: Rathi, Manish, et al.
Publicado: (2018) -
Mycophenolate mofetil in the treatment of lupus nephritis
por: Yong, Patrick FK, et al.
Publicado: (2008) -
Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial
por: Sedhain, Arun, et al.
Publicado: (2018)